Journal of Antimicrobial Chemotherapy (2002) 49, 981-987
© 2002 The British Society for Antimicrobial Chemotherapy
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996–1999
1Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo Km. 2, 28220 Madrid, Spain; 2Departamento Micología, Instituto Nacional de Enfermedades Infecciosas, ANLIS ‘Dr Carlos G. Malbrán’, Avenida Vélez Sarfield, Buenos Aires, Argentina
Received 5 October 2001; returned 4 February 2002; revised 26 February 2002; accepted 14 March 2002.
The aim of this study was to identify retrospectively trends in species distribution and susceptibility patterns of Candida species causing bloodstream infections in 99 medical centres (55 in Spain and 44 in Argentina) from 1996 to 1999. A total of 744 Candida isolates were sent to the mycology reference laboratories during the study period (514 to the Spanish laboratory and 230 to the Argentinian laboratory). Candida non-albicans strains caused more episodes of fungaemia than Candida albicans isolates in both Spain and Argentina. C. albicans was isolated in 30.2% (155/514) and 40.9% (94/230) of episodes in Spain and in Argentina, respectively. In addition, Candida parapsilosis was the second most commonly isolated pathogen (36.4%). Candida tropicalis caused 13.7% of infections and Candida glabrata 7.4%. The amphotericin B MIC was 
1 mg/L for 97.5% of isolates, and 8.3% of strains had decreased susceptibility to flucytosine. Regarding susceptibility to azole agents, 9.9% (74/744) and 21.9% (163/744) exhibited decreased susceptibility to fluconazole and itraconazole, respectively. For Candida species, some marked differences were found between countries, and decreased susceptibility to azole agents was detected significantly more frequently (P < 0.05) among Argentinian isolates of C. albicans, C. parapsilosis and C. tropicalis. These findings reinforced the need for continued surveillance programmes to analyse the factors that may have an influence on candidaemia incidence. Susceptibility patterns were obtained by means of the proposed reference procedure for antifungal susceptibility testing of the European Committee on Antibiotic Susceptibility Testing (EUCAST). Excellent interlaboratory agreement was achieved for MICs for quality control strains noted in Spain and in Argentina (intraclass correlation coefficient of 0.97), indicating that the EUCAST procedure is a reliable methodology for susceptibility testing.
* Present address. Laboratorio de Micología, Hospital San Martín, Pte Perón 450, Paraná, Entre Ríos, Argentina.
Corresponding author. Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. de Majadahonda a Pozuelo Km. 2, 28220 Majadahonda, Spain. Tel: +34-91-5097961; Fax: +34-91-5097966; E-mail: juanl.rodriguez-tudela{at}isciii.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. R. Lockhart, S. A. Messer, M. A. Pfaller, and D. J. Diekema Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates J. Clin. Microbiol., January 1, 2009; 47(1): 242 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Ruan, C.-C. Chu, and P.-R. Hsueh In Vitro Susceptibilities of Invasive Isolates of Candida Species: Rapid Increase in Rates of Fluconazole Susceptible-Dose Dependent Candida glabrata Isolates Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2919 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B.-v. Zepelin, L. Kunz, R. Ruchel, U. Reichard, M. Weig, and U. Gross Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005 J. Antimicrob. Chemother., August 1, 2007; 60(2): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Odds, M. F. Hanson, A. D. Davidson, M. D. Jacobsen, P. Wright, J. A. Whyte, N. A. R. Gow, and B. L. Jones One year prospective survey of Candida bloodstream infections in Scotland J. Med. Microbiol., August 1, 2007; 56(8): 1066 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.-C. Chang, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol., October 1, 2006; 44(10): 3551 - 3556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.M. Coogan, P.L. Fidel Jr., M.C. Komesu, N. Maeda, and L.P. Samaranayake (B1) Candida and Mycotic Infections Advances in Dental Research, April 1, 2006; 19(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuenca-Estrella, D. Rodriguez, B. Almirante, J. Morgan, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003 J. Antimicrob. Chemother., February 1, 2005; 55(2): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Tortorano, A. L. Rigoni, E. Biraghi, A. Prigitano, M. A. Viviani, and the FIMUA-ECMM candidaemia study group The European Confederation of Medical Mycology ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood J. Antimicrob. Chemother., October 1, 2003; 52(4): 679 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Chen, S.-C. Chang, K.-T. Luh, and W.-C. Hsieh Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years J. Antimicrob. Chemother., July 1, 2003; 52(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|